Physician profile
Devin Squires
NPI 1598262305
$3,214.98
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $1,803 · 2023: $544 · 2024: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,132.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,442.94 | 2022-2024 | Interstim |
| Axonics, INC. | $930.88 | 2022-2024 | Axonics |
| Abbott Laboratories | $116.74 | 2023 | Freestyle Libre 3 |
| Amgen INC. | $101.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $97.24 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $90.70 | 2022 | |
| Genzyme Corporation | $88.25 | 2024 | |
| Biogen, INC. | $58.93 | 2021 | |
| Urovant Sciences INC | $55.45 | 2022 | |
| Convatec INC. | $52.59 | 2021-2023 | |
| Gilead Sciences, INC. | $40.15 | 2021 | |
| Astellas Pharma US INC | $37.47 | 2023 | Veozah |
| Neurocrine Biosciences, INC. | $35.06 | 2021 | |
| 180 Medical, INC. | $24.07 | 2021 | |
| Laborie Medical Technologies Corp. | $23.29 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $19.69 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Squires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.